Trending

breast

Cancer market commentary: 3 highlights from ESMO (Part 1)

Cancer market commentary: 3 highlights from ESMO (Part 1)

Commentary on key cancer data from ESMO by Stephanie Hawthorne

X

Cancer market commentary: 3 highlights from ESMO (Part 1)

https://pharmaphorum.com/esmo-2016/cancer-market-commentary-3-highlights-esmo-conference-part-1/

Medivation in merger talks with Sanofi and others

Medivation in merger talks with Sanofi and others

Sources say Pfizer and Celgene are also interested.

X

Medivation in merger talks with Sanofi and others

https://pharmaphorum.com/news/medivation-takeover-talks-sanofi-others/

Possible new breast cancer use for AZ’s Faslodex

Possible new breast cancer use for AZ’s Faslodex

AstraZeneca has announced results from a phase 3 trial of its breast cancer drug candidate Faslodex (fulvestrant). The drug

X

Possible new breast cancer use for AZ’s Faslodex

https://pharmaphorum.com/news/possible-new-breast-cancer-use-for-azs-faslodex-after-phase-iii-success/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com